Lirio, a behavioural science and AI platform, has released research revealing that traditional personalisation approaches in life sciences fail to improve patient engagement. The survey of over 75 life sciences executives, conducted by Sage Growth Partners, found that more than 70% identified clinical trial engagement and medication adherence as persistent challenges. The report highlights that nearly 50% of patients don't take medications as prescribed, contributing to $100 billion in annual preventable healthcare costs and 125,000 avoidable deaths. Despite growing direct-to-consumer strategies, only half of organisations use digital health technologies for patient engagement, and fewer than 3% partner with specialised vendors. The findings come as new regulations reshape pharmaceutical advertising, prompting life sciences companies to rethink patient engagement strategies beyond traditional mass messaging approaches.

Lirio, the Knoxville-based pioneer in the union of behavioral science and artificial intelligence to deliver better health outcomes, has released new industry findings on the significant impact that advanced health... The post Lirio releases report titled (Re)defining Personalization appeared first on Teknovation.biz.